voyager therapeutics stock forecast

Voyager Therapeutics, Inc.

Upcoming earnings, about voyager therapeutics, inc..

See all ideas  

Analyst rating

Stock brokers.

See all brokers  

Frequently Asked Questions

Voyager Therapeutics, Inc.

NasdaqGS:VYGR Stock Report

Market Cap: US$461.2m

Voyager Therapeutics Future Growth

Future criteria checks 0/6.

Voyager Therapeutics's revenue and earnings are forecast to decline at 40.4% and 40.3% per annum respectively. EPS is expected to decline by 40.2% per annum. Return on equity is forecast to be -27.3% in 3 years.

Key information

Earnings growth rate

EPS growth rate

Recent future growth updates

Consensus revenue estimates fall by 21%, price target increased by 9.8% to us$11.17, price target increased to us$8.20, consensus revenue estimates increase by 170%, consensus forecasts updated, recent updates, voyager therapeutics, inc. presents data for second-generation, tracer™-generated capsids and cns gene therapy programs advancing toward clinical trials at the asgct 27th annual meeting, voyager therapeutics, inc. to report q1, 2024 results on may 13, 2024, investor sentiment improves as stock rises 16%, voyager therapeutics, inc., annual general meeting, jun 05, 2024, president recently sold us$119k worth of stock, president notifies of intention to sell stock, voyager therapeutics, inc. announces appointment of toby ferguson as chief medical officer, effective march 25, 2024, there's no escaping voyager therapeutics, inc.'s (nasdaq:vygr) muted revenues despite a 28% share price rise.

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

What does the future hold for voyager therapeutics, inc. (nasdaq:vygr) these analysts have been cutting their estimates.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Voyager therapeutics, inc. announces selection of gene therapy development candidate for friedreich's ataxia in collaboration with neurocrine biosciences, triggering milestone payment, investor sentiment improves as stock rises 18%, president recently sold us$97k worth of stock, voyager therapeutics, inc. to report q4, 2023 results on feb 28, 2024, voyager therapeutics reports robust preclinical activity in tau silencing gene therapy program for alzheimer's disease and advances program into late research, new minor risk - share price stability, voyager therapeutics, inc. has filed a follow-on equity offering in the amount of $100 million., voyager therapeutics, inc. has completed a follow-on equity offering in the amount of $100 million., voyager therapeutics, inc. (nasdaq:vygr) surges 45% yet its low p/s is no reason for excitement.

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings: eps in line with analyst expectations despite revenue beat, voyager therapeutics, inc. to report q3, 2023 results on nov 06, 2023, chief financial officer recently sold us$95k worth of stock, chief financial officer notifies of intention to sell stock, chief scientific officer notifies of intention to sell stock, new major risk - revenue and earnings growth, second quarter 2023 earnings: eps and revenues exceed analyst expectations, voyager therapeutics, inc. to report q2, 2023 results on aug 03, 2023, voyager therapeutics announces appointment of jacquelyn fahey sandell as chief legal officer, chief science officer notifies of intention to sell stock, investor sentiment deteriorates as stock falls 16%, investor sentiment improves as stock rises 25%, voyager therapeutics, inc. appoints george scangos as director and as member of science and technology committee, first quarter 2023 earnings: eps and revenues exceed analyst expectations, president recently sold us$58k worth of stock, chief operating officer recently sold us$126k worth of stock, full year 2022 earnings: eps and revenues miss analyst expectations, voyager therapeutics, inc. appoints grace e. colón, ph.d., to its board of directors, effective on january 1, 2023, third quarter 2022 earnings: eps and revenues exceed analyst expectations, voyager therapeutics, inc. to report q3, 2022 results on nov 08, 2022, voyager therapeutics, inc presents data characterizing a novel cns receptor and demonstrating the low-dose potential of tracer™ generated capsid families, voyager stock rises as pfizer opts to use aav capsid for neurologic disease target, voyager therapeutics appoints peter pfreundschuh as cfo, effective september 19, 2022, voyager therapeutics hires new finance chief, consensus revenue estimates fall by 86%, second quarter 2022 earnings released: us$0.50 loss per share (vs us$0.80 loss in 2q 2021), voyager therapeutics gaap eps of -$0.50 misses by $0.02, voyager therapeutics presents new data demonstrating novel candidate therapeutic antibodies reduced tau pathology in multiple preclinical models, voyager therapeutics, inc. to report q2, 2022 results on aug 04, 2022, voyager therapeutics appoints catherine j. mackey, ph.d. to its board of directors, voyager therapeutics, inc. announces executive changes, looking back in on voyager therapeutics, voyager therapeutics, inc. to present new preclinical data on family of aav9-derived tracer capsids demonstrating cross-species central nervous system (cns) transduction, voyager therapeutics, inc. to present preclinical data from its vectorized anti-her2 antibody program and a novel aav5-derived tracer™ capsid at the 25th american society of gene and cell therapy annual meeting, need to know: analysts just made a substantial cut to their voyager therapeutics, inc. (nasdaq:vygr) estimates.

Consensus revenue estimates fall by 37%

First quarter 2022 earnings: eps and revenues miss analyst expectations, price target increased to us$6.80, voyager therapeutics, inc., annual general meeting, jun 06, 2022, mark levin and steven paul requests voyager therapeutics not to nominate for re-election to the board, voyager does a reboot after first generation failures, consensus revenue estimates increase by 87%, full year 2021 earnings: revenues exceed analysts expectations while eps lags behind, companies like voyager therapeutics (nasdaq:vygr) could be quite risky.

Voyager Therapeutics, Inc. Announces Executive Appointments

Price target decreased to us$6.00, voyager therapeutics: another year, another deal, third quarter 2021 earnings released: us$0.67 loss per share (vs us$2.30 profit in 3q 2020), investor sentiment deteriorated over the past week, price target increased to us$7.07, investor sentiment improved over the past week, some analysts just cut their voyager therapeutics, inc. (nasdaq:vygr) estimates.

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020)

Price target increased to us$10.31, newsflash: voyager therapeutics, inc. (nasdaq:vygr) analysts have been trimming their revenue forecasts.

Consensus revenue estimates fall to US$17.5m

Voyager therapeutics, inc.(nasdaqgs:vygr) dropped from russell 3000e index, earnings and revenue growth forecasts, analyst future growth forecasts.

Earnings vs Savings Rate : VYGR's earnings are forecast to decline over the next 3 years (-40.3% per year).

Earnings vs Market : VYGR's earnings are forecast to decline over the next 3 years (-40.3% per year).

High Growth Earnings : VYGR's earnings are forecast to decline over the next 3 years.

Revenue vs Market : VYGR's revenue is expected to decline over the next 3 years (-40.4% per year).

High Growth Revenue : VYGR's revenue is forecast to decline over the next 3 years (-40.4% per year).

Earnings per Share Growth Forecasts

Future return on equity.

Future ROE : VYGR is forecast to be unprofitable in 3 years.

Discover growth companies

High growth companies in the Pharmaceuticals-biotech industry.

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Voyager Therapeutics Inc

Ever heard of finviz*elite.

Our premium service offers you real-time quotes, advanced visualizations, technical studies, and much more. Become Elite and make informed financial decisions.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

• Voyager Therapeutics-stock
• News for Voyager Therapeutics

VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Voyager Therapeutics (NASDAQ: VYGR ) just reported results for the first quarter of 2024.

• Voyager Therapeutics reported earnings per share of -20 cents. This was above the analyst estimate for EPS of -44 cents.
• The company reported revenue of $19.52 million.
• This was 107.40% better than the analyst estimate for revenue of $9.41 million.

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected].

More From InvestorPlace

• The #1 AI Investment Might Be This Company You’ve Never Heard Of
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”

The post VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024 appeared first on InvestorPlace .

Voyager Therapeutics News MORE

Related stocks.

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here . By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service .

Member Sign In

Don't Know Your Password?

• Zacks #1 Rank
• Zacks Industry Rank
• Zacks Sector Rank
• Equity Research
• Mutual Funds
• Mutual Fund Screener
• ETF Screener
• Earnings Calendar
• Earnings Releases
• Earnings ESP
• Earnings ESP Filter
• Stock Screener
• Premium Screens
• Basic Screens
• Research Wizard
• Personal Finance
• Money Management
• Retirement Planning
• Tax Information
• My Portfolio
• Create Portfolio
• Style Scores
• Testimonials
• Zacks.com Tutorial

Services Overview

• Zacks Ultimate
• Zacks Investor Collection
• Zacks Premium

Investor Services

• ETF Investor
• Home Run Investor
• Income Investor
• Stocks Under $10
• Value Investor
• Top 10 Stocks

Other Services

• Method for Trading
• Zacks Confidential

Trading Services

• Black Box Trader
• Counterstrike
• Headline Trader
• Insider Trader
• Large-Cap Trader
• Options Trader
• Short Sell List
• Surprise Trader
• Alternative Energy

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK . If you do not, click Cancel.

Voyager Therapeutics (VYGR)

(delayed data from nsdq).

+0.06 (0.70%)

Updated May 16, 2024 04:00 PM ET

After-Market: $8.63 0.00 (0.00%) 7:58 PM ET

Add to portfolio

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D  Value | F  Growth | A  Momentum | D  VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Quote Overview

Stock activity, key earnings data.

Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.

Visit the Earnings ESP Center

See the Full List of Stocks To Beat Earnings

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

Research Report for VYGR

News for VYGR

This file is used for Yahoo remarketing pixel add

Due to inactivity, you will be signed out in approximately:

trading lower

• Positive STOXX 524.71
• Positive FTSE 8,445.80

Voyager Therapeutics Inc

Key statistics.

1.70 mean rating - 10 analysts

2024 (millions USD)

About Voyager Therapeutics Inc (VYGR.OQ)

Company information.

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Contact Information

+ 1 ( 857 ) 2595340

https://www.voyagertherapeutics.com/

Biotechnology & Drugs

Executive Leadership

Income statement.

2023 (millions USD)

Balance Sheet

Source: LSEG New Tab , opens new tab - data delayed by at least 15 minutes

Markets Performance

Commodities chevron, currencies chevron, rates & bonds chevron, stocks chevron.

We couldn’t find any results matching your search.

Please try using other words for your search or explore other sections of the website for relevant information.

We’re sorry, we are currently experiencing some issues, please try again later.

Our team is working diligently to resolve the issue. Thank you for your patience and understanding.

Bid Price and Ask Price

The  bid  &  ask  refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing to pay, whereas the ask is the lowest amount that a seller is currently willing to sell. The numbers next to the bid/ask are the “ size ”. The bid size displays the total amount of desired shares ... Read More. to buy at that price, and the ask size is the number of shares offered for sale at that price. The data displayed in the quote bar updates every 3 seconds; allowing you to monitor prices in real-time. The  bid-ask spread  can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers and sellers in the market are willing to negotiate. In contrast, a larger spread suggests lower liquidity, as there are fewer investors willing to negotiate. You can use the bid-ask spread to determine whether to place a  market order  or  limit order  when trading, helping you to optimize your price and have a successful order execution. Real-time bid and ask information is powered by Nasdaq Basic, a premier market data solution. This data feed is available via Nasdaq Data Link APIs; to learn more about subscribing, visit  Nasdaq Data Link's products page . ... Read Less.

• After-Hours
• Press Releases
• Analyst Research
• Dividend History
• Historical Quotes
• Historical NOCP
• P/E & PEG Ratios
• Option Chain
• Short Interest
• Institutional Holdings
• Insider Activity
• SEC Filings
• Revenue EPS

Symbol Search

Recently viewed.

Analyze your stocks, your way

Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.

Latest News

This data feed is not available at this time.

Trending Stocks

Trending etfs, trending indexes.

• Real-time Data is provided using Nasdaq Last Sale Data

Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at  data.nasdaq.com .

• Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.

These symbols will be available throughout the site during your session.

Your symbols have been updated

Edit watchlist.

• Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.

Opt in to Smart Portfolio

Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use .

NASDAQ: VYGR Voyager Therapeutics Inc Stock

Vygr overview.

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Due Diligence Checks

Be the first to know about important vygr news, forecast changes, insider trades & much more get free vygr updates.

Wedbush Weighs in on Voyager Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VYGR) Defenseworld.net • 12 hours ago

Metric Analysis: Voyager Therapeutics Inc (VYGR)'s Key Ratios in the Limelight – DWinneX The Dwinnex • a day ago

President and CEO, Sandrock Alfred sold 12115 shares of Voyager Therapeutics Inc [VYGR] – Knox Daily Knox Daily • a day ago

Voyager Therapeutics Inc (VYGR) deserves deeper analysis – US Post News US Post News • 2 days ago

Voyager Therapeutics (NASDAQ:VYGR) Given New $8.00 Price Target at Wedbush Defenseworld.net • 2 days ago

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Call Transcript Insider Monkey • 3 days ago

VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024 MSN Money • 3 days ago

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Sees Large Growth in Short Interest Defenseworld.net • 4 days ago

Voyager Therapeutics (VYGR) Set to Announce Quarterly Earnings on Monday Defenseworld.net • 6 days ago

Guggenheim initates Voyager Therapeutics Inc (VYGR) stock to a Buy – Knox Daily Knox Daily • 8 days ago

Virios Therapeutics (VIRI) Scheduled to Post Quarterly Earnings on Thursday Defenseworld.net • 9 days ago

Voyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returns Yahoo Finance UK • 10 days ago

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast Yahoo Finance • 11 days ago

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Earnings Call Transcript Yahoo News • 12 days ago

Examining the Potential Price Growth of Voyager Therapeutics Inc (VYGR) – Knox Daily Knox Daily • 15 days ago

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Can Afford To Invest In Growth Yahoo Finance UK • 19 days ago

Voyager Therapeutics Inc (VYGR)'s results reveal risk – US Post News US Post News • 21 days ago

Allspring Global Investments Holdings LLC Has $821000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) Defenseworld.net • 22 days ago

A company insider recently sold 12115 shares of Voyager Therapeutics Inc [VYGR]. Should You also Consider to Sale ... Knox Daily • 22 days ago

Raymond James Financial Services Advisors Inc. Has $243000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) Defenseworld.net • 23 days ago

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy ... Markets Insider • 24 days ago

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy ... Yahoo Canada Shine On • 25 days ago

Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated at StockNews.com Defenseworld.net • a month ago

Was anything negative for Voyager Therapeutics Inc (VYGR) stock last session? – US Post News US Post News • a month ago

Balance Sheet Insights: Voyager Therapeutics Inc (VYGR)'s Debt-to-Equity and Long-Term Debt/Eq Ratios – DWinneX The Dwinnex • a month ago

VYGR fair value

Fair value of vygr stock based on discounted cash flow (dcf), vygr price to earnings (pe), for valuing profitable companies with steady earnings, vygr price to book (pb), for valuing companies that are loss-making or have lots of physical asset, vygr 's financial health, profit margin, assets to liabilities, vygr vs biotech stocks, voyager therapeutics stock faq.

What is Voyager Therapeutics's quote symbol?

What is the 52 week high and low for Voyager Therapeutics (NASDAQ: VYGR)?

How much is Voyager Therapeutics stock worth today?

How much is Voyager Therapeutics's stock price per share?

What is Voyager Therapeutics's Market Cap?

Stock Tools

Stock ideas.

Vision, Mission, & Strategy

Management Team

Board of Directors

Scientific Advisory Board

Core Values

• VY-TAU01 for Alzheimer’s

• Alzheimer’s early research

• SOD1 for ALS

Patient Resources

Partnerships

TRACER Platform

Non-Viral Delivery

Publications & Presentations

Press Releases

Events & Presentations

Stock Information

Shareholder Services

Job Openings

Our Community

Mission & Values

Disclosures

Release Details

Voyager therapeutics reports first quarter 2024 financial and operating results.

- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks -

- Development candidates selected for Neurocrine-partnered GBA1 and Friedreich’s Ataxia gene therapy programs; potential for three gene therapies, including SOD1-ALS, to enter the clinic in 2025 -

Toby Ferguson , M.D., Ph.D., as Chief Medical Officer -

- Strong cash position of approximately $400 million as of March 31, 2024 ; expected to provide runway through multiple clinical data readouts into 2027 -

LEXINGTON, Mass. , May 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported first quarter 2024 financial and operating results.

Alfred W. Sandrock , Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Our gene therapy pipeline is also advancing, with development candidates selected in the GBA1 and Friedreich’s Ataxia programs partnered with Neurocrine, as well as in our wholly-owned SOD1-ALS program. We expect to achieve IND filings for all three of these gene therapy programs in 2025. We maintain a strong cash position of approximately $400 million at quarter-end, with runway into 2027, which we anticipate will enable us to reach multiple data readouts in 2025 and 2026.”

First Quarter 2024 and Recent Highlights

• Obtained IND clearance for VY-TAU01 for Alzheimer’s disease: Received clearance of the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for VY-TAU01, an anti-tau antibody for the treatment of Alzheimer’s disease.
• Development candidate selected in GBA1 gene therapy program: Announced that the joint steering committee with collaborator Neurocrine Biosciences selected a lead development candidate for the GBA1 gene therapy program for the treatment of Parkinson’s disease and other GBA1-mediated diseases, triggering a $3 million milestone payment to Voyager.
• Development candidate selected in FXN gene therapy program: Announced that the joint steering committee with collaborator Neurocrine Biosciences selected a lead development candidate for the FXN gene therapy program for the treatment of Friedreich’s Ataxia, triggering a $5 million milestone payment to Voyager.
• Strategic collaboration and capsid license agreement with Novartis: Announced a strategic collaboration and capsid license agreement with Novartis Pharma AG to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Novartis paid Voyager $80 million of consideration up front and $20 million for the purchase of newly issued equity in Voyager. Voyager is eligible to receive up to $1.2 billion in preclinical, development, regulatory and sales milestones, as well as tiered royalties on global net sales of products incorporating Voyager’s TRACER™ capsids.
• Completion of public offering: Completed an underwritten public offering of shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) for aggregate gross proceeds of approximately $100 million .
• 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024): Presented data demonstrating robust reductions in human tau messenger RNA (mRNA) and protein across the brain following a single intravenous (IV) administration of a tau silencing gene therapy candidate in mice expressing human tau. Also presented data demonstrating that VY-TAU01 was well-tolerated following IV administration in non-human primates (NHPs).
• American Society of Gene & Cell Therapy’s (ASGCT) 27th annual meeting: Presented a broad set of translational data, including new data demonstrating enhanced brain tropism of second-generation TRACER-derived AAV capsids, translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALS.

Anticipated Upcoming Milestones

• VY-TAU01 anti-tau antibody for Alzheimer’s disease: Voyager expects to dose the first subject in a Phase 1a single ascending dose trial in healthy volunteers in the coming weeks and initiate a Phase 1b multiple ascending dose trial in patients with early Alzheimer’s disease in 2025. The multiple ascending dose trial has the potential to generate initial data for slowing the spread of pathological tau via tau PET imaging in 2026.
• VY9323   SOD1 silencing gene therapy program for ALS: Voyager expects to file an IND in mid-2025 and initiate a Phase 1 clinical trial in ALS patients. The Phase 1 trial has the potential to generate proof-of-concept data based on biomarkers.
• Partnered programs: Voyager and Neurocrine Biosciences expect to file INDs for the GBA1 and Friedreich’s Ataxia gene therapy programs in 2025.

First Quarter 2024 Financial Results

• Collaboration Revenues: Voyager had collaboration revenue of $19.5 million for the first quarter of 2024, compared to $150.5 million for the same period in 2023. The decrease was primarily due to the first quarter 2023 recognition of $69.5 million from the 2023 Neurocrine Collaboration Agreement and $79.0 million from Novartis’ exercise of two capsid options.
• Net (Loss) Income: Net loss was $11.3 million for the first quarter of 2024, compared to net income of $124.0 million for the same period in 2023. The decrease is primarily due to reduced collaboration revenue recognized in the first quarter of 2024, as discussed above.
• R&D Expenses: Research and development expenses were $27.1 million for the first quarter of 2024, compared to $18.6 million for the same period in 2023. The increase in R&D expenses was primarily a result of increased program-related spending, particularly manufacturing and IND-enabling studies for the VY-TAU01 anti-tau antibody program, the VY9323 SOD1-ALS gene therapy program, and the initiation of spend on the Novartis HD program during the first quarter of 2024, along with increased headcount costs.
• G&A Expenses: General and administrative expenses were $8.6 million for the first quarter of 2024, compared to $9.0 million for the same period in 2023.
• Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2024 , were $400.5 million .

Financial Guidance

Voyager is committed to maintaining a strong balance sheet that supports the advancement and growth of its platform and pipeline. Voyager continues to assess its planned cash needs both during the current period and in future periods. We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations, certain near-term milestones, and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2027.

Conference Call

Voyager will host a conference call and webcast today at 4:30 p.m. ET to discuss first quarter 2024 financial and operating results. To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI1f6af80e7a614ca7925cbad2f35a55c6 . Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com , and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

About the TRACER™ Capsid Discovery Platform

Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of novel AAV capsids to enable gene therapy. Voyager has leveraged TRACER to create multiple families of novel capsids that, following intravenous delivery in preclinical studies, harness the extensive vasculature of the central nervous system (CNS) to cross the blood-brain barrier and transduce a broad range of CNS regions and cell types. In cross-species preclinical studies (rodents and multiple non-human primate species), intravenous delivery of TRACER-generated capsids resulted in widespread payload expression across the CNS at relatively low doses, enabling selection of multiple development candidates in Voyager’s wholly-owned and partnered gene therapy programs for neurologic diseases.

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG ; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.  

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “expect,” “will,” “believe,” “anticipate,” “potential,” “trigger” or “continue,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding Voyager’s ability to advance its AAV-based gene therapy programs and tau antibody program, including expectations for Voyager’s achievement of preclinical and clinical development milestones for its potential development candidates such as IND filings, the initiation of clinical trials, and generation of clinical data and proof-of-concept; Voyager’s ability to advance gene therapy product candidates under the Neurocrine and Novartis collaborations; Voyager’s anticipated financial results, including the anticipated receipt by Voyager of revenues or reimbursement payments from collaboration partners; and Voyager’s cash runway and ability to generate sufficient cash resources to enable it to continue its business and operations are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the expectations and decisions of regulatory authorities; the timing, initiation, conduct and outcomes of Voyager’s preclinical and clinical studies; the availability of data from clinical trials; the availability or commercial potential of product candidates under collaborations; the willingness and ability of Voyager's collaboration partners to meet obligations under collaboration agreements with Voyager; the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; Voyager’s scientific approach and program development progress, and the restricted supply of critical research components; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the success of programs controlled by third party collaboration partners in which Voyager retains a financial interest, and the success of Voyager’s product candidates; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission . All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Brooke Shenkin , [email protected]

GAAP vs. Non-GAAP Financial Measures Voyager’s financial statements are prepared in accordance with generally accepted accounting principles in the United States , or GAAP, and represent revenue and expenses as reported to the Securities and Exchange Commission . Voyager has provided in this release certain financial information that has not been prepared in accordance with GAAP, including net collaboration revenue and net research and development expenses, which exclude the impact of reimbursement by Neurocrine Biosciences (Neurocrine) for expenses we incur in conducting preclinical development activities under our collaboration agreements. Management uses these non-GAAP measures to evaluate the Company’s operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in its business. Management believes that such non-GAAP measures are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing the Company’s operating performance. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation. The non-GAAP measures give investors and financial analysts a better understanding of our net revenue and net research and development expenses without the pass-through impact of Neurocrine costs. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures set forth below.

Note 1: Under the Company's existing collaboration agreements with Neurocrine and Novartis, Neurocrine and Novartis have agreed to be responsible for all costs the Company incurs in conducting preclinical development activities for certain collaboration programs, in accordance with joint steering committee agreed upon workplans and budgets. Reimbursable research and development services performed during the period are captured within collaboration revenue and research and development expenses in the Company's consolidated statements of operations. During the three months ended March 31, 2024 , we incurred $3.2 million of reimbursable research and development services recorded within collaboration revenue and research and development expenses. During the three months ended March 31, 2023 , we incurred $0.3 million of reimbursable research and development services recorded within collaboration revenue and research and development expenses.

Source: Voyager Therapeutics, Inc.